[ADIPONECTIN AND A VIOLATION OF METABOLIC CONTROL AT DIFFERENT STAGES OF NONALCOHOLIC FATTY LIVER DISEASE IN PATIENTS...

Area of Science:

• Endocrinology
• Hepatology
• Metabolic Disorders

Background:

• Nonalcoholic fatty liver disease (NAFLD) is a growing concern in patients with type 2 diabetes mellitus (DM).
• Adiponectin, an adipocytokine, plays a crucial role in metabolic regulation and its levels are often altered in NAFLD and DM.
• Understanding the interplay between NAFLD progression, adiponectin secretion, and metabolic status is vital for patient prognosis.

Purpose of the Study:

• To determine adiponectin levels in patients with type 2 diabetes across different stages of NAFLD.
• To assess the impact of adiponectin on metabolic alterations, including carbohydrate, lipid, and protein metabolism.
• To investigate the relationship between adiponectin levels and liver function in this patient cohort.

Main Methods:

• Cross-sectional study design.
• Measurement of serum adiponectin levels.
• Assessment of metabolic parameters (e.g., glucose, lipids, proteins) and liver function tests.
• Stratification of patients based on NAFLD stage.

Main Results:

• Adiponectin levels were found to vary significantly with the stage of NAFLD in patients with type 2 diabetes.
• Lower circulating adiponectin levels correlated with specific metabolic disturbances and impaired liver function.
• These findings highlight the diagnostic and prognostic relevance of adiponectin in comorbid NAFLD and type 2 diabetes.

Conclusions:

• Adiponectin levels are a significant indicator of NAFLD progression and metabolic dysregulation in type 2 diabetes patients.
• Monitoring adiponectin may improve diagnostic capabilities for identifying at-risk individuals.
• Further research into adiponectin's role can enhance prevention strategies and patient quality of life.